Core Viewpoint - Jiyuan Holdings officially terminates its listing on the Shenzhen Stock Exchange due to its stock price falling below 1 yuan for 20 consecutive trading days, resulting in a cumulative loss of nearly 3.7 billion yuan over six years [1][4]. Group 1: Company Background - Jiyuan Holdings began as a chemical company and transitioned into the pharmaceutical sector through the acquisition of Jinbao Pharmaceutical in 2014, establishing a dual business model of "chemicals + pharmaceuticals" [2][3]. - In 2017, the company rebranded as Jiyuan Holdings, marking a significant shift towards the health industry and initiating an aggressive acquisition strategy that expanded its business into eight major segments [3]. Group 2: Financial Performance - From 2019 to 2024, Jiyuan Holdings reported a total net loss of 3.668 billion yuan, with a staggering asset-liability ratio of 204.08% by the end of 2024, indicating severe financial distress [4]. - In 2024, the company generated only 333 million yuan in revenue while incurring a net loss of 439 million yuan, with available cash dwindling to 16.7 million yuan against short-term borrowings of 600 million yuan [4]. Group 3: Governance and Legal Issues - The company faced governance issues, including the arrest of its former chairman and a board member for alleged job-related crimes, which were discovered during an internal audit [4]. - Jiyuan Holdings has been under investigation by the China Securities Regulatory Commission due to various compliance issues [4]. Group 4: Attempts at Recovery - Over six years, the company made several attempts to recover, including a failed acquisition of Xiu Zheng Pharmaceutical and a strategic cooperation agreement with local government to mitigate delisting risks [5][6]. - The last attempt at restructuring in June 2023 was unsuccessful due to insolvency issues, leading to the termination of the pre-restructuring process by the court in March 2025 [6][7]. Group 5: Delisting Process - Jiyuan Holdings' stock price fell below 1 yuan on March 19, 2025, and remained low for 20 consecutive trading days, triggering the delisting process without a grace period [7]. - The company appointed Shanxi Securities as its main broker and signed an agreement for stock transfer to a delisting board prior to its official delisting on May 29, 2025 [7].
股价连续跌破1元 大举并购的吉药控股退市